Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 6/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10423871 | 0.80 | CA2 (0.44) | ALDH1A1TMEM97SIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL10424541 | 0.80 | CA2 (0.44) | ALDH1A1TMEM97SIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL10423865 | 0.80 | CA2 (0.44) | ALDH1A1TMEM97SIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL13381099 | 0.75 | PABPC1 (0.59) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL18885118 | 0.75 | PABPC1 (0.59) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL1487109 | 0.73 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL8625830 | 0.73 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL8192982 | 0.73 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL714617 | 0.73 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL8200760 | 0.73 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | PABPC1 942/4885CTDSP1 382/4885GAA 1238/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | PABPC1 1822/4885CTDSP1 157/4885GAA 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.